Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1].
in vivo
Leronlimab (2 mg; i.p., twice a week) reduces lung metastasis in murine xenograft models[1].
Reduced the volume of pulmonary metastases at 8 weeks.
References
[1] Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23(1):11. DOI:10.1186/s13058-021-01391-1
